Key Takeaways:
Zealand Pharma A/S began its registrational Phase 3a ZUPREME program for petrelintide, launching three placebo-controlled trials that will enroll about 7,000 people with overweight or obesity and are designed to support marketing applications for the once-weekly amylin analog in chronic weight management.
"The Phase 3a program is designed to confirm the first-choice potential of petrelintide — supported by the data we have seen throughout the clinical trials with petrelintide: clinically meaningful double-digit weight reduction and a tolerability profile that supports the long-term adherence that chronic weight management requires," David Kendall, MD, Chief Medical Officer at Zealand Pharma, said.
The Copenhagen-based company (Nasdaq: ZEAL) is running the program with Roche Holding AG under a 2025 collaboration and licensing agreement to co-develop and co-commercialize petrelintide. ZUPREME-3, the largest of the three, will enroll roughly 3,900 participants with a body mass index of at least 27 with one weight-related comorbidity, or at least 30, without type 2 diabetes. ZUPREME-4 takes about 600 participants with overweight or obesity and type 2 diabetes. ZUPREME-5 enrolls about 2,500 people with overweight or obesity and established cardiovascular disease, with or without type 2 diabetes.
All three trials measure percentage change in body weight from baseline to week 64 as the primary endpoint. ZUPREME-3 and ZUPREME-4 run a screening period, 12 weeks of dose escalation, then maintenance through week 64 and safety follow-up to week 77. Participants completing the week 64 visit can enter an optional open-label extension offering petrelintide regardless of their original treatment arm. ZUPREME-5 adds an event-maintenance phase after the week 64 primary assessment and can run up to three years. Secondary endpoints include waist circumference, HbA1c, cardiometabolic risk factors, physical functioning and eating behaviors.
The design leans on Phase 2 results that showed double-digit weight loss with a tolerability profile largely comparable to placebo — the combination Zealand argues is the differentiator in a market where gastrointestinal side effects drive discontinuation. Petrelintide is a long-acting amylin analog engineered for chemical and physical stability with no fibrillation around neutral pH, which allows co-formulation and co-administration with other peptides. Human amylin is co-secreted with insulin by pancreatic beta cells; amylin receptor activation reduces body weight by restoring sensitivity to the satiety hormone leptin, producing earlier fullness.
The Phase 3 start arrived alongside a competing data point from the same partner. Genentech, a member of the Roche Group, reported that enicepatide (CT-388), a once-weekly dual GLP-1/GIP receptor agonist, cut HbA1c by 2.65% and body weight by 15.5% at 48 weeks at the 24 mg dose in the Phase 2 CT-388-104 trial of 447 adults with type 2 diabetes and overweight or obesity. Treatment discontinuation from adverse events was 2.0% in enicepatide arms versus 0.0% on placebo.
Zealand and Roche plan a Phase 2 trial combining petrelintide with enicepatide in the second half of 2026, a pairing that would put the amylin asset alongside the incretin rather than against it. The competitive bar is set by Eli Lilly's tirzepatide, which produced 16% to 22.5% mean weight reduction in the SURMOUNT-1 trial in people without diabetes, and by Novo Nordisk's semaglutide, both of which hold approvals in diabetes and chronic weight management with years of real-world prescribing data behind them.
Zealand has more than ten invented drug candidates that have entered clinical development, two products on the market and three candidates in late-stage development. The company reported no stock price reaction in the announcement, and no enrollment completion date or regulatory filing timeline has been disclosed.
For holders, the ZUPREME program converts petrelintide from a Phase 2 tolerability story into a registrational asset with a defined path to a chronic weight management filing, and the 7,000-participant scale signals Zealand and Roche expect the data to carry a label broad enough to compete for first-line use. The next visible milestones are the start of the petrelintide-enicepatide combination trial in the second half of 2026 and any disclosure of ZUPREME enrollment pace, which will indicate whether the week 64 primary readouts can land before the end of the decade.
This article is for informational purposes only and does not constitute investment advice.
